Principles of care for the diagnosis and treatment of von Willebrand disease

Haematologica

Volumn 98, Issue 5, 2013, Pages 667-674

  Castaman, Giancarlo ^a   Goodeve, Anne ^b   Eikenboom, Jeroen ^c  

^a SAN BORTOLO HOSPITAL   (Italy)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; AMINOCAPROIC ACID; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 PLUS VON WILLEBRAND FACTOR; DESMOPRESSIN; EMOSINT; ESTROGEN; FACTOR 8Y; FANHDI; GESTAGEN; GRIFOLS; HEPATITIS A VACCINE; HEPATITIS B VACCINE; IRON; LEVONORGESTREL; LOW MOLECULAR WEIGHT HEPARIN; ORAL CONTRACEPTIVE AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 8; RISTOCETIN; THROMBOCYTE CONCENTRATE; TRANEXAMIC ACID; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; WILFACTIN;

CONTINUOUS INFUSION; DISEASE CLASSIFICATION; EPISTAXIS; FLUSHING; HEADACHE; HEMOPHILIA A; HEMOSTASIS; HUMAN; HYPONATREMIA; LOADING DRUG DOSE; MENORRHAGIA; MOLECULAR DIAGNOSIS; PROPHYLAXIS; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SUBSTITUTION THERAPY; TACHYCARDIA; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; VON WILLEBRAND DISEASE;

EID: 84877026971     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.077263     Document Type: Review

References (61)

1. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood. 1987;69(2):454-9.
2. Castaman G, Eikenboom JCJ, Bertina RM, Rodeghiero F. Inconsistency of association between type 1 von Willebrand disease phenotype and genotype in families identified in an epidemiological investigation. Thromb Haemost. 1999;82(3):1065-70.
3. De Meyer SF, Deckmyn H, Vanhoorelbeke K. von Willebrand factor to the rescue. Blood. 2009;113(21):5049-57.
4. Mannucci PM. Treatment of von Willebrand's Disease. N Engl J Med. 2004; 351(7):683-94.
5. Pasi KJ, Collins PW, Keeling DM, Brown SA, Cumming AM, Dolan GC, et al. Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia. 2004; 10(3):218-31.
6. Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4(10):2103-14.
7. Nichols WL, Hultin MB, James AH, Manco- Johnson MJ, Montgomery RR, Ortel TL, et al. von Willebrand disease (VWD): evidencebased diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia. 2008;14(2):171-232.
8. Rodeghiero F, Castaman G, Tosetto A. How I treat von Willebrand disease. Blood. 2009; 114(6):1158-65.
9. Mannucci PM, Franchini M, Castaman G, Federici AB. Evidence-based recommendations on the treatment of von Willebrand disease in Italy. Blood Transf. 2009:7(2):117-26.
10. Federici AB, Lee CA, Berntorp EE, Lillicrap D, Montgomery RR. Von Willebrand disease. Oxford, UK; Wiley-Blackwell, 2011.
11. Wahlberg T, Blomback M, Hall P, Axelsson G. Application of indicators, predictors and diagnostic indices in coagulation disorders. I. Evaluation of a self-administered questionnaire with binary questions. Methods Infect Med. 1980;19(4):194-200.
12. Sramek A, Eikenboom JC, Briet E, Vandenbroucke JP, Rosendaal FR. Usefulness of patient interview in bleeding disorders. Arch Intern Med. 1995;155(13):1409-15.
13. Rodeghiero F, Castaman G, Tosetto A, Batlle J, Baudo F, Cappelletti A, et al. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. J Thromb Haemost. 2005;3(12):2619-26.
14. Tosetto A, Castaman G, Rodeghiero F. Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes theorem approach. Blood. 2008;111(8):3998-4003.
15. Tosetto A, Rodeghiero F, Castaman G. Bleeding scores in inherited bleeding disorders: clinical or research tools? Haemophilia. 2008;14(3):415-22.
16. Rodeghiero F, Tosetto A, Abshire T, Arnold DM, Coller B, James P, et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost. 2010;8(9):2063-5.
17. Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB, Budde U, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost. 2006;4(4):766-73.
18. Goodeve A, Eikenboom J, Castaman G, Rodeghiero F, Federici AB, Batlle J, et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood. 2007;109(1):112-21.
19. Biss TT, Blanchette VS, Clark SD, Bowman M, Wakefield CD, Silva M, et al. Quantitation of bleeding symptoms in children with von Willebrand disease: use of a standardized pediatric bleeding questionnaire. J Thromb Haemost. 2010;8(6):950-6.
20. Castaman G, Tosetto A, Federici AB, Rodeghiero F. Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance. Thromb Haemost. 2011;105(4):647-54.
21. Castaman G, Federici AB, Tosetto A, La Marca S, Stufano F, Mannucci PM, et al. Different bleeding risk in type 2 A and 2 M Von Willebrand disease: a two-year prospective study in 107 patients. J Thromb Haemost. 2012;10(4):632-8.
22. Mancuso DJ, Tuley EA, Westfield LA et al. Human von Willebrand factor gene and pseudogene: structural analysis and differentiation by polymerase chain reaction. Biochemistry 1991;30(1):253-69.
23. Goodeve A. The genetic basis of von Willebrand disease. Blood Rev. 2010;24(3): 123-34.
24. Keeney S, Bowen D, Cumming A, Enayat S, Goodeve A, Hill F. The molecular analysis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organisation Haemophilia Genetics Laboratory Network. Haemophilia. 2008; 14(4):1099-11.
25. Budde U, Favaloro EJ. Laboratory diagnosis of von Willebrand disease: the phenotype. In Federici AB, Lee CA, Berntorp EE, Lillicrap D, Montgomery RR (eds). Von Willebrand disease. Oxford, UK; Wiley-Blackwell, 2011, 100-13.
26. Rodeghiero F, Castaman G, Di Bona E, Ruggeri M. Consistency of responses to repeated DDAVP infusions in patients with von Willebrand's disease and hemophilia A. Blood. 1989;74(6):1997-2000.
27. Federici AB, Mazurier C, Berntorp E, Lee CA, Scharrer I, Goudemand J, et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood. 2004 (6);103: 2032-8.
28. Castaman G, Lethagen S, Federici AB, Tosetto A, Goodeve A, Budde U, et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood. 2008(7);111: 3531-9.
29. Castaman G, Tosetto A, Rodeghiero F. Reduced von Willebrand factor survival in von Willebrand disease: pathophysiologic and clinical relevance. J Thomb Haemost. 2009;7:(Suppl 1):71-4.
30. Castaman G, Rodeghiero F. Desmopressin and type II B von Willebrand disease. Hemophilia. 1996;2(2):73-6.
31. Federici AB, Mannucci PM, Castaman G, Baronciani L, Bucciarelli P, Canciani MT, et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood. 2009;113(5):526-34.
32. Mannucci PM, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol. 1992;82(1):87-93.
33. Smith TJ, Gill JC, Ambruso DR, Hathaway WE. Hyponatremia and seizures in young children given DDAVP. Am J Hematol. 1989; 31(3):199-202.
34. Bond L, Bevan D. Myocardial infarction in a patient with hemophilia treated with DDAVP. N Eng J Med. 1988;318(2):121.
35. Byrnes JJ, Larcada A, Moake JL. Thrombosis following desmopressin for uremic bleeding. Am J Hematol. 1988;28(1):63-5.
36. Mannucci PM. Use of desmopressin (DDAVP) during early pregnancy in factor VIII-deficient women. Blood. 2005; 105(8):3382.
37. Castaman G, Tosetto A, Rodeghiero F. Pregnancy and delivery in women with von Willebrand's disease and different von Willebrand factor mutations. Haematologica. 2010; 95(6) 963-9.
38. Makris M, Conlon CP, Watson HG. Immunization of patients with bleeding disorders. Haemophilia. 2003;9(5):541-6.
39. Steele M, Cochrane A, Wakefield C, Stain AM, Ling S, Blanchette V, Gold R, Ford-Jones L. Hepatitis A and B immunization for individuals with inherited bleeding disorders. Haemophilia. 2009;15(2):437-47.
40. Federici AB. The safety of plasma-derived von Willebrand/factor VIII concentrates in the management of inherited von Willebrand disease. Expert Opin Drug Saf. 2009(2); 8: 203-10.
41. Mannucci PM, Franchini M. The use of plasma- derived concentrates. In: Federici AB, Lee CA, Berntorp EE, Lillicrap D, Mongomery RR. Von Willebrand disease. Oxford, UK; Wiley-Blackwell, 2011:200-6.
42. Castaman G. Treatment of von Willebrand disease with FVIII/VWF concentrates. Blood Transf. 2011;9(Suppl 2):s9-s13.
43. Goudemand J, Scharrer I, Berntorp E, Lee CA, Borel-Derlon A, Stieltjes N, et al. Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virusinactivation/ removal methods. J Thromb Haemost. 2005;3(10):2219-27.
44. Borel-Derlon A, Federici AB, Roussel-Robert V, Goudemand J, Lee CA, Scharrer I, et al. Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost. 2007; 5(6):1115-24.
45. Makris M, Colvin B, Gupta V, Shields ML, Smith MP. Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease. Thromb Haemost. 2002;88(3):387-8.
46. Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb Haemost. 2002;88(3):378-9.
47. Berntorp E, Petrini P. Long-term prophylaxis in von Willebrand disease. Blood Coag Fibrinol. 2005;16(Suppl 1):S23-6.
48. Federici AB. Highly purified VWF/FVIII concentrates in the treatment and prophylaxis of von Willebrand disease. The PRO.WILL study. Haemophilia. 2007;13(Suppl 5):15-24.
49. Abshire TC, Federici AB, Alvarez MT, Bowen J, Carcao MD, Cox Gill J, et al. Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand disease prophylaxis network (VWD PN). Haemophilia. 2013;19(1):76-81.
50. Mannucci PM, Tamaro G, Narchi G, Candotti G, Federici A, Altieri D, et al. Lifethreatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factor. Eur J Hematol. 1987;39(5):467-70.
51. Mohl A, Boda Z, Jager R, Losonczy H, Marosi A, Masszi T, et al. Common large partial VWF gene deletion does not cause alloantibody formation in the Hungarian type 3 von Willebrand disease population. J Thromb Haemost. 2011;9(5):945-52.
52. Ciavarella N, Schiavoni M, Valenzano E, Mangini F, Inchingolo F. Use of recombinant factor VIIa (NovoSeven) in the treatment of two patients with type III von Willebrand's disease and an inhibitor against von Willebrand factor. Haemostasis. 1996;26 (Suppl 1):10-4.
53. Franchini M, Gandini G, Giuffrida A, De Gironcoli M, Federici AB. Treatment for patients with type 3 von Willebrand disease and alloantibodies: a case report. Haemophilia. 2008;14(3):645-6.
54. Castillo R, Monteagudo J, Escolar G, Ordinas A, Magallón M, Martín Villar J. Hemostatic effect of normal platelet transfusion in severe von Willebrand disease patients. Blood. 1991;77(9):1901-5.
55. Mannucci PM. Hemostatic drugs. N Eng J Med. 1998;339(4):245-53.
56. Kadir RA, Lee CA, Sabin CA, Pollard D, Economides DL. Pregnancy in women with von Willebrand's disease or factor XI deficiency. Br J Obstet Gynaecol. 1998;105(3): 314-21.
57. De Wee EM, Knol HM, Mauser-Bunschoten EP, van der Bom JG, Eikenboom JC, Fijnvandraat K, et al. Gynaecological and obstetric bleeding in moderate and severe von Willebrand disease. Thromb Haemost. 2011;106(5):885-92.
58. Kingman CE, Kadir RA, Lee CA, Economides DL. The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. Br J Obstet Gynaecol. 2004;111(12): 1425-8.
59. Kadir RA, Economides DL, Sabin CA, Owens D, Lee CA. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet. 1998,351(9101):485-9.
60. Giles AR, Hoogendoorn H, Benford K. Type IIB von Willebrand's disease presenting as thrombocytopenia during pregnancy. Br J Haematol. 1987;67(3):349-53.
61. Sánchez-Luceros A, Meschengieser SS, Turdó K, Arizó A, Woods AI, Casais P, et al. Evaluation of the clinical safety of desmopressin during pregnancy in women with a low plasmatic von Willebrand factor level and bleeding history. Thromb Res. 2007; 120(3):387-90.